共 129 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA: A Cancer J Clin 68 7-30
[2]
Miller KD(2018)Cancer incidence and mortality in China, 2014 Chin J Cancer Res 30 1-12
[3]
Jemal A(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[4]
Chen W(2017)NCCN Guidelines Insights: Breast Cancer, Version 1.2017 J Natl Compr Canc Netw 15 433-451
[5]
Sun K(2014)Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG) Breast Cancer Res Treat 148 591-597
[6]
Zheng R(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials The Lancet 379 432-444
[7]
Zeng H(2012)Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials Breast 21 389-393
[8]
Zhang S(2013)Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial J Clin Oncol 31 3197-3204
[9]
Xia C(2010)Longer therapy, iatrogenic amenorrhe, and survival in early breast cancer N Engl J Med 362 2053-2065
[10]
Yang Z(2013)Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial Ann Oncol 24 1203-1211